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Giacomo Caio1,2,3, Umberto Volta1,2,3*, Francesco Tovoli1,2,3 and Roberto De Giorgio1,2,3Abstract
Background: Non-celiac gluten sensitivity is a syndrome characterized by gastrointestinal and extra-intestinal
symptoms occurring in a few hours/days after gluten and/or other wheat protein ingestion and rapidly improving
after exclusion of potential dietary triggers. There are no established laboratory markers for non-celiac gluten
sensitivity, although a high prevalence of first generation anti-gliadin antibodies of IgG class has been reported in
this condition. This study was designed to characterize the effect of the gluten-free diet on anti-gliadin antibodies
of IgG class in patients with non-celiac gluten sensitivity.
Methods: Anti-gliadin antibodies of both IgG and IgA classes were assayed by ELISA in 44 non-celiac gluten
sensitivity and 40 celiac disease patients after 6 months of gluten-free diet.
Results: The majority of non-celiac gluten sensitivity patients (93.2%) showed the disappearance of anti-gliadin
antibodies of IgG class after 6 months of gluten-free diet; in contrast, 16/40 (40%) of celiac patients displayed
the persistence of these antibodies after gluten withdrawal. In non-celiac gluten sensitivity patients anti-gliadin
antibodies IgG persistence after gluten withdrawal was significantly correlated with the low compliance to
gluten-free diet and a mild clinical response.
Conclusions: Anti-gliadin antibodies of the IgG class disappear in patients with non-celiac gluten sensitivity
reflecting a strict compliance to the gluten-free diet and a good clinical response to gluten withdrawal.
Keywords: Anti gliadin antibodies, Non-celiac gluten sensitivity, Celiac diseaseBackground
The spectrum of gluten-related disorders has recently
acquired a new entity represented by non-celiac gluten
sensitivity (NCGS) [1-3]. This is an emerging syndrome
evoked by gluten ingestion in patients in whom both
celiac disease (CD) and wheat allergy have been excluded
[4-6]. In addition to gluten, other triggers involved in
NCGS pathogenesis have been recently identified includ-
ing wheat proteins (i.e. amylase- and trypsin- inhibitors)
[7] and fermentable oligo-, di-, mono-saccharides and
polyols (FODMAPs) [8,9]. NCGS is characterized by gas-
tro-esophageal reflux disease (i.e., retrosternal pyrosis and* Correspondence: umberto.volta@aosp.bo.it
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stated.regurgitation) and irritable bowel syndrome (IBS) like
symptoms (i.e., abdominal pain, bloating, diarrhea, consti-
pation and alternating bowel) along with extra-intestinal
manifestations (“foggy mind”, headache, fatigue, joint and
muscle pain, leg/arm numbness, eczema/rash, depression/
anxiety and anemia) that occur soon after gluten in-
gestion, rapidly improving after gluten withdrawal and
relapsing in a few hours or days after gluten challenge
[2]. NCGS and CD seems to be different because of epi-
demiologic and pathogenetic aspects. NCGS is thought to
be more frequent than CD, although its actual prevalence
is still poorly defined [3,10]; CD recognizes pathogenic
mechanisms which have been defined over the years,
while the mechanisms underlying NCGS remain largely
unsettled [2]. Furthermore, patients diagnosed as NCGS
must prove to be negative for anti-endomysial (EmA) and
anti-tissue transglutaminase antibodies (tTGA) and haved. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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intestinal mucosa [9]. Specific IgE and/or prick tests
should be tested in order to exclude wheat allergy [6]. A
double-blind, placebo controlled challenge is suggested to
confirm diagnosis, since no biomarker is so far available
for establishing a firm diagnosis of NCGS [11,12].
Serology has been of paramount importance for CD
diagnosis, thus we postulate that antibody screening
might help to detect at least a subset of NCGS patients.
For more than 20 years, prior to highly specific tests (i.e.,
EmA and tTGA), the detection of anti-gliadin antibodies
(AGA) has been instrumental to stratify patients with sus-
pected CD. Their positivity was a diagnostic criterion for
endoscopic evaluation confirming CD in the majority of
cases [13]. However, the usefulness of this test has been
hampered by false-positive cases ranging from 5 to 20%,
especially for IgG, rather than IgA, AGA [14]. Nonethe-
less, we have recently shown that 56% and 8% of NCGS
patients had IgG and IgA AGA positivity, respectively
[15], findings in line with results shown by others [3,12].
Our study was designed to evaluate the effect of gluten
withdrawal on AGA detected in the serum of NCGS
patients. Moreover, we investigated whether a correl-
ation exists between AGA persistence and compliance
to gluten-free diet (GFD) as well as AGA persistence
and clinical response to GFD.
Methods
Patients
We studied 44 cases of NCGS (female/male 28/16, me-
dian age 38 years - range 17 to 63 years), all positive for
AGA IgG (only 4 were positive also for AGA IgA),
selected from a series of 78 NCGS patients analyzed in a
previously published paper [15]. The diagnosis of NCGS
was established after a thorough work-up in our CD
outpatient clinic (a tertiary referral center for CD of the
Emilia-Romagna Region in Italy at the Department of
Medical and Surgical Sciences at St. Orsola-Malpighi
Hospital) between January 2009 and June 2011. All the
44 patients included in the present study were negative
for CD serology (EmA and tTGA of IgA class) and for
wheat allergy tests (specific IgE and skin prick tests) on
a gluten containing diet. All these patients were referred
to our attention because of intestinal and extraintestinal
symptoms with an early onset (a few hours or days) after
gluten ingestion. Small intestinal biopsy, tested in all of
them on a gluten-containing diet, showed either a
normal mucosa (Marsh 0) (n = 26) (58%) or mild abnor-
malities (n = 18) (42%), with an increased number of intra-
epithelial lymphocytes (Marsh 1) [16].
A serum sample was collected from the 44 NCGS
patients after 6 months of GFD and was reassessed for
AGA IgG and IgA. The persistence of AGA was corre-
lated with dietary adherence and clinical response toGFD. Dietary adherence to the GFD was assessed in all
NCGS patients through a structured questionnaire,
which was conducted by a dietician with experience in
educating patients with gluten-related disorders. Patients
were classified as strict compliers (people who after the
beginning of GFD had never ingested gluten knowingly)
and low compliers (those who admitted frequent dietary
lapses). The clinical response of NCGS patients to GFD
was evaluated on the basis of the persistence or disappear-
ance of the gastrointestinal (pyrosis, regurgitation, bloating,
abdominal pain, diarrhoea, constipation, alternating bowel)
and extra-intestinal symptoms (“foggy mind”, headache,
fatigue, joint and muscle pain, leg/arm numbness, eczema/
rash, depression/anxiety and anemia) scored from 0 to 3 as
follows: 0 = absent; 1 = occasionally present, without wors-
ening quality of life; 2 = frequently present, with a mod-
erate worsening of quality of life; 3 = always present,
with a severe worsening of quality of life. Patients
with NCGS were classified as “good responder” to
GFD when all the symptoms experienced on a gluten con-
taining diet disappeared or significantly improved after
GFD with a decrease of the initial global score higher than
50%. Those showing a decrease of the initial global score
lower than 50% were classified as “mild responder”.
The immune response to gliadin after 6 months of
GFD was also evaluated in 40 age- and sex-matched CD
patients, all positive for AGA IgG when untreated (of
whom 30 were positive for AGA IgA). The diagnosis of
CD had been confirmed in the 40 CD patients included in
the present study by the demonstration of villous atrophy
and the positivity for EmA IgA and tTGA IgA on a gluten
containing diet. AGA persistence in CD patients after
gluten withdrawal was correlated with dietary adherence
and clinical response to GFD, by using the same approach
adopted for NCGS patients.
As no individual patient identification was involved
and all assays where part of clinical routine practice, a
simplified International Review Board approval by the St.
Orsola-Malpighi Hospital Ethics Committee was obtained.
Serological tests
AGA IgG and IgA were determined in NCGS and CD
patients by commercially available kits of enzyme-linked
immunosorbent assay (ELISA) (α-gliatest SIgG and SIgA,
Eurospital, Trieste, Italy) using purified α-gliadin as anti-
gen. The cut-off levels, as suggested by the manufacturer,
were fixed at 50 arbitrary units (AU) for IgG and 15 AU
for IgA [17].
Statistical analysis
The two-tailed Fisher’s exact test was used to evaluate the
correlation between AGA persistence and the compliance
with GFD as well as the clinical improvement after gluten
withdrawal in both NCGS and CD patients.
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AGA IgG persisted positive only in 3 (6.8%) out of the
44 NCGS patients tested after 6 months of gluten with-
drawal (Figure 1). AGA IgG persistence after GFD was
significantly correlated with the low degree of com-
pliance with gluten-free diet and with a mild clinical
response (P = 0.009 and P = 0.00075, two-tailed Fisher’s
exact test, respectively) (Table 1). AGA IgG disappeared
in 40 out of the 41 NCGS patients who followed a strict
GFD and remained positive in 2 out of the 3 low com-
pliers admitting frequently dietary lapses. Of the 39
NCGS patients classified as good responders to the diet
on the basis of the disappearance or significant im-
provement of intestinal and extra-intestinal symptoms,
none maintained the positivity for AGA IgG. On the
contrary, these antibodies were still detected in 3 out of
the 5 patients assessed as mild responders to gluten
withdrawal due to a partial resolution of clinical symp-
toms. In the CD group the persistence of AGA IgG after
6 months of GFD did not show any correlation either
with the compliance to the diet or the clinical response
following the gluten-free regimen (Figure 2). AGA IgG
persistence was detected in 13 (40.6%) out of the 32
strict compliers and in 3 (37.5%) out of the 8 low com-
pliers. There was no significant difference for AGA IgG































Figure 1 IgG antigliadin antibodies before and after GFD in NCGS pat
gluten free diet (GFD) in patients with non-celiac gluten sensitivity (N
AGA IgG at a low titre after gluten withdrawal.AGA IgA were positive in only 4 of the 44 NCGS
patients on gluten-containing diet. These antibodies re-
mained positive in one patient who admitted a low com-
pliance to GFD and had a mild clinical response. In the
other 3 NCGS patients, who adhered strictly to GFD and
had a very good clinical impact on symptoms, the AGA
IgA became negative (Figure 3). In the celiac group the
persistence of AGA IgA after gluten withdrawal was
strictly related to the low compliance with the diet and
with the mild clinical response to the dietary treatment
(P = 0.000036 and P = 00018, two-tailed Fisher’s exact
test, respectively) (Figure 4). Only 4 out of the 30
AGA IgA positive CD patients showed the persistence
of these antibodies; all of them showed a mild clinical
response and were not complying with the GFD.
Discussion
Despite the progressive awareness of its existence, NCGS
is still a condition with many unanswered questions. In
contrast to CD, the prevalence of NCGS is far from being
established since few reliable epidemiologic studies have
been so far published [3,10]. Indeed, the National Health
and Nutrition Examination Survey has identified 49 cases
of NCGS over 7,762 subjects (age range 6-80 years) in the
2009-2010 period with a weighted prevalence of 0.55%
[10]. In a tertiary care center for celiac research, the
criteria for NCGS were met by 347 over 5,896 patientsAfter GFD
ients: anti-gliadin antibodies (AGA) of IgG class before and after
CGS). Only three of the 44 patients studied showed persistence of
Table 1 AGA IgG in NCGS and CD related to compliance to the GFD and clinical picture
44 NCGS patients (all with AGA IgG when untreated) after
6-months-GFD
Good response to GFD 39 /44 Mild response to GFD 5/44
Compliance AGA IgG + AGA IgG- AGA IgG + AGA IgG-
Strict 41/44 0 38 1 2
Low 3/44 0 1 2 0
40 CD patients (all with AGA IgG on a gluten containing diet) after
6-months-GFD
Good response to GFD 30/40 Mild response to GFD 10/40
Compliance AGA IgG+ AGA IgG- AGA IgG + AGA IgG-
Strict 32/40 11 14 2 5
Low 8/40 2 3 1 2
AGA IgG in NCGS patients with low compliance vs. AGA IgG in NCGS patients with strict compliance, P = 0.009; AGA IgG in NCGS patients with mild response to
GFD vs IgG AGA in NCGS patients with good response to GFD. NCGS, P = 0.00075. Two tailed Fisher’s exact test.
AGA IgG in CD patients with low compliance vs. AGA IgG in CD patients with strict compliance, P = NS; AGA IgG in CD patients with mild response to GFD vs AGA
IgG in CD patients with good response to GFD, P = NS. Two tailed Fisher’s exact test.
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5.9% [3]. This latter figure should be cautiously taken as a
patient selection bias may have occurred. In our last year
(2012) experience at the Celiac Disease Centre of St.
Orsola-Malpighi Hospital in Bologna, the ratio between
the new NCGS and CD cases was 1.6 to 1, confirming a
slightly higher prevalence of NCGS vs. CD [9].
A further aspect of distinction between CD and NCGS
is given by the pathogenetic mechanisms underlying these






























Figure 2 IgA antigliadin antibodies before and after GFD in NCGS pat
gluten free diet (GFD) in patients with non-celiac gluten sensitivity (Nimmunity are well known to have a major role in CD, only
innate immunity has been thought to be activated by glu-
ten proteins in NCGS [3]. However, even adaptive im-
munity may play a role in NCGS as recently suggested
[18]. In support of this possibility, previous papers have
shown that antibodies, such as AGA, can be detected in
more than half of NCGS patients [3,9,12,15]. Although
AGA cannot be considered a specific marker for NCGS
(as these antibodies can be found in many other condi-
tions including autoimmune disorders and even in healthyAfter GFD






























Before GFD After GFD
Figure 3 IgG antigliadin antibodies before and after GFD in CD patients: anti-gliadin antibodies (AGA) of IgG class before and after






























Before GFD After GFD
Figure 4 IgA antigliadin antibodies before and after GFD in CD patients: anti-gliadin antibodies (AGA) of IgA class before and after
gluten free diet (GFD) in patients with celiac disease (CD).
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symptoms can be helpful for confirming a diagnosis of
NCGS [3,12,15,19]. However, there are no data concern-
ing the effect of the GFD on AGA in NCGS and whether
AGA persistence after GFD correlates with a low compli-
ance to gluten-withdrawal and clinical manifestations in
this new gluten-related syndrome. In this context, our
study provides new findings showing that GFD can
improve significantly both gastrointestinal and extra-
intestinal symptoms in patients with NCGS. A possible
link between gluten and symptoms has been suggested in
NCGS patients [11], although other components, mainly
contained in the wheat (i.e. proteins), may trigger
symptoms in NCGS. For example, wheat amylase-
and trypsin-inhibitors, a complex of proteins trigger-
ing innate immunity, could contribute to symptom
generation in NCGS [7]. Similarly to IBS, it is likely
that FODMAPs may also play a role in evoking
gastrointestinal (as well as extra-intestinal) symptoms
in patients with NCGS [8,20]. In this line, recent evidence
by Bisierkieski et al. showed that a diet low in FODMAPs
resulted in an improvement of the clinical picture of
NCGS in IBS patients, thus supporting a major role of
these dietary factors, rather than gluten [21].
In a previous series of untreated NCGS patients we
demonstrated that about 50% of cases resulted posi-
tive for AGA IgG [15]. Those patients were followed
up and retested for AGA in the present study where
we highlighted that NCGS and CD have a different
immune response to gliadin after GFD. Interestingly,
concerning NCGS, the detection of AGA IgG identifies a
possible subgroup of such patients. The vast majority of
NCGS patients showed AGA IgG disappearance after
gluten withdrawal, whereas the same antibodies persisted
in 40% of CD patients after GFD. In NCGS patients the
negativization of AGA IgG after gluten withdrawal was
significantly related to the strict compliance to the diet as
demonstrated by the antibody persistence in only one out
of the 41 patients with a strong adherence to the diet and
in two of the 3 who did not adhere strictly to GFD. More-
over, AGA IgG disappearance in treated NCGS patients
was closely related to the good response to GFD with a
significant improvement of the clinical picture (i.e., symp-
tom score decreased more than a half compared to that of
gluten-containing diet). None of the 39 NCGS patients
classified as good responders to the diet maintained AGA
IgG positivity, whereas these antibodies persisted in 3 out
of the 5 NCGS patients assessed as mild responders to the
diet. In contrast to NCGS, AGA IgG in celiac patients per-
sisted after GFD regardless the adherence and the clinical
response to gluten withdrawal. The different behaviour of
AGA IgG identified in patients with CD vs. NCGS in
response to GFD may reflect the different pathogenic
mechanisms underlying these two disorders. In fact, CD isa well-recognized autoimmune disease, whereas NCGS is
likely a gluten hypersensitivity without an established in-
volvement of autoimmunity [2,5]. The persistence of AGA
IgG in a large proportion of CD patients following GFD
can be regarded as an expression of the immunological
memory of the autoimmune disorder, whereas the gluten
withdrawal in NCGS switches off the immune process
and this effect is supposed to lead to the rapid disappear-
ance of AGA [22]. In contrast with AGA IgG, AGA IgA
disappearance can be viewed as the result of a strict GFD
as well as of a good clinical response in both NCGS and
CD patients. Indeed, these antibodies disappeared in all
the NCGS patients with a strict adherence to GFD and a
good clinical response, remaining positive only in one
patient with admitted low dietary compliance and mild
clinical response to the diet. Similarly, the finding of AGA
IgA in the celiac group on GFD was closely related to the
low compliance with the diet and the mild clinical res-
ponse to the dietary treatment. Our study focused on a
specific subset of NCGS patients, i.e. those with AGA IgG
positivity and whether GFD may have an effect on NCGS-
related symptoms in the "antibody-negative" subset of
gluten sensitive patients remains unknown. It is tentative
to speculate that even in AGA-negative NCGS patients
gluten withdrawal can improve the symptom profile.
Clearly, further studies testing this hypothesis are eagerly
awaited. The fluctuation of AGA with dietary changes
(i.e. gluten withdrawal and re-challenge) in NCGS patients
remains another very interesting aspect. In a recent double
blind, placebo controlled study, Biesiekierski et al. have
shown that NCGS patients in gluten-withdrawal for 6 weeks
and re-challenged with high dose of gluten (16 g/day for
one week) had an increase of AGA IgG and IgA in 8% and
21% of cases, respectively [21]. These are lower proportions
of NCGS patients compared to those detected in patients
during a gluten containing diet. Thus, the data provided by
Biesiekierski et al. appear quite different from our results,
indicating about 50% of NCGS patients with positive AGA
IgG. A possible explanation for such discrepancy may be
the very short period (one week) of gluten challenge used
by Biesiekierski et al. [21]. Probably, this short-time gluten
exposure in NCGS patients was not enough to evoke the
reactivation of the adaptive immunity to produce AGA
in response to gliadin. This exciting possibility should
deserve further study.Conclusions
In conclusion, AGA IgG disappearance in patients with
NCGS can be viewed as a sign of strict compliance to the
GFD and an expression of a good clinical response to
gluten withdrawal. The AGA IgG persistence in NCGS
indicates that gluten is still introduced in the diet, and this
prevents clinical improvement.
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